Researchers applied network medicine to map 6,442 existing drugs against the hallmarks of aging, identifying candidates that may influence longevity by targeting proteins proximal to aging-related gene modules. This approach offers a systematic method to repurpose approved medications for age-related interventions without requiring decades-long human trials.
Key Points
- Network proximity scoring identifies drugs targeting aging hallmark neighborhoods
- 1,250 aging genes assigned to specific hallmarks; 390 span multiple hallmarks
- TP53 and interconnected genes suggest shared molecular machinery across aging
Longevity Analysis
The challenge in aging research has always been scale—thousands of genes, hundreds of biological processes, and the impracticality of testing individual drugs over human lifespans. This network-based approach reorganizes that chaos by mapping protein interactions as neighborhoods rather than isolated targets. By connecting existing drugs to these molecular neighborhoods, researchers can now filter thousands of candidates for their proximity to validated aging mechanisms, dramatically reducing the uncertainty in predicting which compounds warrant further investigation. The method inherently captures how aging hallmarks interconnect through shared proteins, reflecting the reality that cellular senescence, DNA damage, and metabolic dysfunction do not operate in isolation. This transforms drug discovery from guesswork into evidence-informed prioritization.
Original published by LifeSpan.io, by Arkadi Mazin.